DelveInsight’s “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma, historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma, offering comprehensive insights into the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma revenue trends, prevalence, and treatment landscape. The report delves into key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CAR T-Cell Therapy for Non-Hodgkin’s lymphoma therapies. Additionally, we cover the landscape of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma space.
Get a Free sample for the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market
Some of the key facts of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report:
The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market size is anticipated to grow with a significant CAGR during the study period (2022-2036).
In April 2026, the US FDA granted full approval to TECARTUS for adult patients with relapsed or refractory MCL, supported by efficacy, safety, and pharmacokinetic data from the ZUMA-2 study, including patients who are BTKi-naïve after one or more prior lines of therapy.
In February 2026, Gilead Sciences (Kite) announced that the US FDA approved an update to YESCARTA labeling, removing the prior limitation of use in patients with relapsed or refractory primary CNS lymphoma (PCNSL), reinforcing its safety profile and making it the only CAR T-cell therapy with this restriction removed for large B-cell lymphoma.
In December 2025, the US FDA approved BREYANZI as the first CART-cell Therapy in the US for adults with MZL who have relapsed or failed after two or more prior lines of therapy, where it works by engineering a patient’s T cells to target and destroy cancer cells.
According to the estimates, the United States accounted for the largest CAR T-cell therapy market in NHL, valued at approximately USD 1,900 million in 2025, and is expected to grow at a significant CAGR.
The CAR T-cell therapy market in NHL is rapidly evolving as treatment approaches shift from conventional chemo-immunotherapy to highly targeted, cell-based therapies, with increasing adoption driven by strong efficacy in relapsed/refractory settings, expansion into earlier lines of therapy (2L, 3L+), and advancements in next-generation and allogeneic CAR T platforms.
Regional market dynamics indicate that the United States leads in revenue and adoption due to early approvals and robust healthcare infrastructure, while Japan and EU markets are witnessing steady growth, supported by rising disease incidence, improving access to advanced therapies, and increasing uptake of novel CAR T-cell treatments.
According to DelveInsight estimates, the total incident cases of selected CAR-T indications in NHL across the 7MM were approximately 159,000 in 2025 and are expected to rise throughout the forecast period from 2026 to 2036.
Across the 7MM, CAR T-cell therapy demonstrates promising potential in multiple NHL indications, including MCL, DLBCL (with the highest number of incident cases around 78,000), FL, PMBCL, MZL, and CLL/SLL.
The United States had the highest incidence of selected CAR-T indications in NHL, with approximately 68,000 cases in 2025.
Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Companies: Gilead Sciences (Kite Pharma), Novartis, BMS, Allogene Therapeutics, Novartis, Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others
Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies: YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel, Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others
The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CAR T-Cell Therapy for Non-Hodgkin’s lymphoma pipeline products will significantly revolutionize the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market dynamics.
According to DelveInsight’s estimates, the total number of NHL cases eligible for CAR-T therapy in the 7MM was approximately 125,900 in 2023.
DLBCL is the most common subtype of non-Hodgkin lymphoma in the EU4 and UK, with around 32,400 cases reported in 2023.
In 2023, Japan reported around 23,700 incident cases of NHL across selected subtypes.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Overview
Chimeric Antigen Receptor (CAR) T-cell therapy is an innovative treatment for certain types of Non-Hodgkin’s lymphoma. It involves modifying a patient’s own T-cells (a type of immune cell) to express a receptor that targets and kills cancerous B-cells, which are typically present in NHL. These modified T-cells are then infused back into the patient, where they recognize and destroy lymphoma cells. CAR T-cell therapy has shown promising results for patients with relapsed or refractory NHL, particularly for aggressive forms of the disease. It is considered a breakthrough in cancer immunotherapy due to its ability to harness the body’s immune system for targeted treatment.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
To Know in detail about the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Segmentation:
The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Incidence of Promising Indications for CAR-T in NHL
Mantle cell lymphoma (MCL)
Diffuse large B-cell lymphoma (DLBCL)
Follicular Lymphoma (FL)
Primary mediastinal large B-cell lymphoma (PMBCL)
Marginal Zone Lymphoma (MZL)
Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
Download the report to understand which factors are driving CAR T-Cell Therapy for Non-Hodgkin’s lymphoma epidemiology trends @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Forecast
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market or expected to get launched during the study period. The analysis covers CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies and Key Companies
YESCARTA (axicabtagene ciloleucel): Gilead Sciences (Kite Pharma)
KYMRIAH (tisagenlecleucel): Novartis
BREYANZI: BMS
Cemacabtagene ansegedleucel: Allogene Therapeutics
Rapcabtagene autoleucel: Novartis
Human CD19Targeted T Cells Injection: Hrain Biotechnology
Mosunetuzumab: Lazaros Lekakis
IM19 CAR-T Cells: Beijing Immunochina Medical Science
lisocabtagene maraleucel: Juno Therapeutics
YESCARTA: Gilead Sciences
KYMRIAH: Novartis
Rapcabtagene autoleucel (YTB323): Novartis
Zamtocabtagene autoleucel: Miltenyi Biomedicine
AUTO4: Autolus Therapeutics
CD30.CAR-T: Tessa Therapeutics
Discover more about therapies set to grab major CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market share @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Treatment Landscape
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers
Rising prevalence of Non-Hodgkin’s lymphoma (NHL) worldwide, increasing the demand for advanced treatment options.
Strong clinical efficacy of CAR T-cell therapies in relapsed or refractory NHL patients who have limited treatment alternatives.
Growing number of regulatory approvals for CAR T-cell therapies targeting various NHL subtypes.
Increasing investment in cell and gene therapy research by biotechnology and pharmaceutical companies.
Advancements in CAR T-cell engineering, including improved safety profiles, persistence, and targeting capabilities.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers
High treatment costs associated with CAR T-cell therapy manufacturing, administration, and patient monitoring.
Complex and time-intensive manufacturing processes that can delay treatment delivery.
Limited availability of specialized treatment centers equipped to administer CAR T-cell therapies.
Risk of severe adverse events, including cytokine release syndrome (CRS) and neurotoxicity, requiring intensive clinical management.
Stringent regulatory requirements and lengthy approval pathways for cell-based therapies.
Scope of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma current marketed and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma emerging therapies
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Dynamics: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market drivers and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs, KOL’s views, Analyst’s views, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement
To know more about CAR T-Cell Therapy for Non-Hodgkin’s lymphoma companies working in the treatment market, visit @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report Introduction
2. Executive Summary for CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
3. SWOT analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
4. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Patient Share (%) Overview at a Glance
5. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Overview at a Glance
6. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Disease Background and Overview
7. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
9. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Current Treatment and Medical Practices
10. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs
11. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Emerging Therapies
12. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Outlook
13. Country-Wise CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Analysis (2022–2036)
14. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement of Therapies
15. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers
16. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers
17. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Appendix
18. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679 Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
